|Protein binding||27% (manganese)
|Half-life||20 minutes (manganese)
50 minutes (DPDP)
|Excretion||Renal and fecal (manganese)
|(what is this?)|
Mangafodipir (sold under the brand name Teslascan as mangafodipir trisodium) is a contrast agent delivered intravenously to enhance contrast in magnetic resonance imaging (MRI) of the liver. It has two parts, paramagnetic manganese (II) ions and the chelating agent fodipir (dipyridoxyl diphosphate, DPDP). Normal liver tissue absorbs the manganese more than abnormal or cancerous tissue. The manganese shortens the longitudinal relaxation time (T1), making the normal tissue appear brighter in MRIs. This enhanced contrast allows lesions to be more easily identified.
- "January 2005: Additions and Deletions to the Drug Product List". U.S Food and Drug Administration.
- "Teslascan (mangafodipir): Withdrawal of the marketing authorisation in the European Union" (PDF). European Medicines Agency.
|This pharmacology-related article is a stub. You can help Wikipedia by expanding it.|